Blood TPO Levels and Laboratory Data in Patients With Advanced Carcinomas With or Without Thrombocytosis
| Patient No. . | Age/ Sex . | Tumor . | Plasma TPO (fmol/mL) . | Platelet (×109/L) . | WBC (×109/L) . | Neutrophil (%) . | Hb (g/dL) . | CRP (mg/dL) . |
|---|---|---|---|---|---|---|---|---|
| 1 | 63/M | Stomach, carcinomatous pleuritis | 1.84 | 654 | 16.0 | 91 | 8.9 | 4.3 |
| 2 | 62/F | Lung, carcinomatous pleuritis | 3.18 | 600 | 9.5 | 59 | 11.4 | 3.4 |
| 3 | 47/F | Uterus | 8.67 | 798 | 11.1 | 83 | 9.9 | 4.4 |
| 4 | 59/F | Uterus | 4.20 | 712 | 12.6 | 54 | 12.6 | 0.4 |
| 5 | 58/M | Esophagus, multiple lymph node metastasis | 4.98 | 523 | 10.5 | 83 | 10.5 | 13.1 |
| 6 | 58/M | Esophagus, multiple lymph node metastasis | 0.34 | 550 | 13.4 | 81 | 13.4 | 4.7 |
| 7 | 58/M | Liver | 3.59 | 695 | 17.2 | 92 | 10.6 | 15.5 |
| 8 | 60/M | Stomach, multiple lymph node metastasis | 3.02 | 782 | 12.0 | 61 | 15.4 | 0.3 |
| 9 | 62/F | Gall bladder, multiple liver metastasis | 3.28 | 701 | 9.4 | 56 | 11.0 | 2.7 |
| 10 | 57/M | Larynx, multiple lung metastasis | 3.50 | 659 | 10.8 | 89 | 10.2 | 6.1 |
| 11 | 57/F | Uterus | 1.03 | 624 | 6.8 | 71 | 11.5 | 1.2 |
| 12 | 47/F | Breast, multiple bone metastasis | 4.10 | 587 | 9.3 | 58 | 8.5 | 8.9 |
| 13 | 47/M | Kidney, lung metastasis | 3.27 | 995 | 4.6 | 61 | 10.1 | 1.6 |
| 14 | 51/F | Uterus | 0.57 | 258 | 7.0 | 52 | 14.3 | 0.3 |
| 15 | 56/M | Kidney | 0.21 | 193 | 5.0 | 41 | 11.3 | 0.3 |
| 16 | 72/M | Lung, carcinomatous pleuritis | 0.88 | 358 | 12.1 | 68 | 12.8 | 4.5 |
| 17 | 69/M | Lung, carcinomatous pleuritis | 0.21 | 180 | 11.6 | 42 | 11.1 | 0.5 |
| 18 | 65/M | Lung, lymph node metastasis | 1.06 | 139 | 4.5 | 62 | 11.8 | 0.5 |
| 19 | 61/F | Stomach | 0.30 | 229 | 6.7 | 39 | 13.9 | 0 |
| 20 | 75/F | Colon, multiple lung metastasis | 1.70 | 243 | 4.6 | 70 | 11.5 | 0 |
| 21 | 59/M | Esophagus | 1.78 | 253 | 4.5 | 56 | 10.5 | 0.4 |
| 22 | 71/F | Stomach | 0.63 | 243 | 4.1 | 40 | 9.8 | 0 |
| 23 | 69/F | Rectum | 1.27 | 140 | 2.6 | 45 | 10.1 | 0.1 |
| 24 | 69/M | Bile duct, multiple liver metastasis | 1.47 | 174 | 6.0 | 68 | 13.2 | 1.4 |
| 25 | 74/F | Stomach, multiple liver metastasis | 1.64 | 307 | 7.5 | 66 | 10.8 | 4.2 |
| 26 | 80/F | Stomach | 0.34 | 225 | 5.7 | 59 | 10.1 | 0.5 |
| 27 | 77/F | Duodenum, liver metastasis | 0.66 | 179 | 4.7 | 77 | 9.8 | 0.9 |
| Patient No. . | Age/ Sex . | Tumor . | Plasma TPO (fmol/mL) . | Platelet (×109/L) . | WBC (×109/L) . | Neutrophil (%) . | Hb (g/dL) . | CRP (mg/dL) . |
|---|---|---|---|---|---|---|---|---|
| 1 | 63/M | Stomach, carcinomatous pleuritis | 1.84 | 654 | 16.0 | 91 | 8.9 | 4.3 |
| 2 | 62/F | Lung, carcinomatous pleuritis | 3.18 | 600 | 9.5 | 59 | 11.4 | 3.4 |
| 3 | 47/F | Uterus | 8.67 | 798 | 11.1 | 83 | 9.9 | 4.4 |
| 4 | 59/F | Uterus | 4.20 | 712 | 12.6 | 54 | 12.6 | 0.4 |
| 5 | 58/M | Esophagus, multiple lymph node metastasis | 4.98 | 523 | 10.5 | 83 | 10.5 | 13.1 |
| 6 | 58/M | Esophagus, multiple lymph node metastasis | 0.34 | 550 | 13.4 | 81 | 13.4 | 4.7 |
| 7 | 58/M | Liver | 3.59 | 695 | 17.2 | 92 | 10.6 | 15.5 |
| 8 | 60/M | Stomach, multiple lymph node metastasis | 3.02 | 782 | 12.0 | 61 | 15.4 | 0.3 |
| 9 | 62/F | Gall bladder, multiple liver metastasis | 3.28 | 701 | 9.4 | 56 | 11.0 | 2.7 |
| 10 | 57/M | Larynx, multiple lung metastasis | 3.50 | 659 | 10.8 | 89 | 10.2 | 6.1 |
| 11 | 57/F | Uterus | 1.03 | 624 | 6.8 | 71 | 11.5 | 1.2 |
| 12 | 47/F | Breast, multiple bone metastasis | 4.10 | 587 | 9.3 | 58 | 8.5 | 8.9 |
| 13 | 47/M | Kidney, lung metastasis | 3.27 | 995 | 4.6 | 61 | 10.1 | 1.6 |
| 14 | 51/F | Uterus | 0.57 | 258 | 7.0 | 52 | 14.3 | 0.3 |
| 15 | 56/M | Kidney | 0.21 | 193 | 5.0 | 41 | 11.3 | 0.3 |
| 16 | 72/M | Lung, carcinomatous pleuritis | 0.88 | 358 | 12.1 | 68 | 12.8 | 4.5 |
| 17 | 69/M | Lung, carcinomatous pleuritis | 0.21 | 180 | 11.6 | 42 | 11.1 | 0.5 |
| 18 | 65/M | Lung, lymph node metastasis | 1.06 | 139 | 4.5 | 62 | 11.8 | 0.5 |
| 19 | 61/F | Stomach | 0.30 | 229 | 6.7 | 39 | 13.9 | 0 |
| 20 | 75/F | Colon, multiple lung metastasis | 1.70 | 243 | 4.6 | 70 | 11.5 | 0 |
| 21 | 59/M | Esophagus | 1.78 | 253 | 4.5 | 56 | 10.5 | 0.4 |
| 22 | 71/F | Stomach | 0.63 | 243 | 4.1 | 40 | 9.8 | 0 |
| 23 | 69/F | Rectum | 1.27 | 140 | 2.6 | 45 | 10.1 | 0.1 |
| 24 | 69/M | Bile duct, multiple liver metastasis | 1.47 | 174 | 6.0 | 68 | 13.2 | 1.4 |
| 25 | 74/F | Stomach, multiple liver metastasis | 1.64 | 307 | 7.5 | 66 | 10.8 | 4.2 |
| 26 | 80/F | Stomach | 0.34 | 225 | 5.7 | 59 | 10.1 | 0.5 |
| 27 | 77/F | Duodenum, liver metastasis | 0.66 | 179 | 4.7 | 77 | 9.8 | 0.9 |
In each patient, TPO concentration in the citrated plasma was measured by an ELISA kit. The lower limits of detection for TPO was 0.2 fmol/mL. The plasma TPO concentrations in healthy volunteers were 0.40 ± 0.28 fmol/mL (mean ± SD, n = 99). The laboratory data are from the samples simultaneously obtained for TPO determination. The normal range of platelet count was 150 to 370 × 109/L. The normal range of CRP was less than 0.5 mg/dL. From patient no. 5, ES-O cell line was established (see Materials and Methods).
Abbreviations: Hb, hemoglobin; CRP, C-reactive protein.